quinazolines has been researched along with Cancer of Mouth in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.41) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (37.84) | 29.6817 |
| 2010's | 19 (51.35) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Lou, Y; Ren, L; Sun, M | 1 |
| Anwar, MF; Siraj, B; Tanveer, F; Zarina, S | 1 |
| Nakajima, M; Nozaki, M; Ohnishi, Y; Yasui, H | 1 |
| Jameson, MJ; Khalil, A | 1 |
| Bertrand, D; Chia, S; Chong, FT; DasGupta, R; Gopalakrishna Iyer, N; Hentze, H; Hui Choo, S; Hwang, JSG; Koh, JLY; Kwang, XL; Leong, HS; Lezhava, A; Lim, KH; Low, JL; Periyasamy, G; Sharma, A; Skanthakumar, T; Su, Y; Tan, DSW; Tan, HK; Tan, IBH; Tan, P; Thangavelu, MT; Toh, SY; Zhang, X | 1 |
| Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X | 1 |
| Cheong, SC; Fadlullah, MZH; Gan, CP; Kelly, GM; Lee, BKB; Lee, HM; Patel, V; Yee, PS; Zainal, NS | 1 |
| Kakudo, K; Minamino, Y; Nozaki, M; Ohnishi, Y | 1 |
| Cui, H; Fu, G; Qiu, Y; Ren, A | 1 |
| Cho, SD; Kim, Y; Lee, JS; Sachita, K; Yu, HJ | 1 |
| Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV | 1 |
| Birkeland, AC; Bradford, CR; Brenner, JC; Carey, TE; Foltin, SK; Komarck, CM; Ludwig, ML; Mann, JE; McHugh, JB; Michmerhuizen, NL; Prince, ME; Sandelski, MM; Scott, MV; Spector, ME; Tillman, BN; Yanik, M | 1 |
| Chavez, J; De La Chapa, JJ; Dybdal-Hargreaves, NF; Gonzales, CB; Horning, AM; Kirma, NB; Parra, J; Saikumar, P; Singha, PK | 1 |
| Kakudo, K; Nozaki, M; Ohnishi, Y; Yasui, H | 1 |
| Amano, O; Chu, Q; Kanda, Y; Kunii, S; Sakagami, H; Wang, Q | 1 |
| Doçi, CL; Hasina, R; Lingen, MW; Mankame, TP; Wroblewski, K; Zhou, G | 1 |
| Bednash, JS; Freilino, ML; Gooding, WE; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Lingen, MW; Neill, DB; Panahandeh, MC; Seethala, RR; Singh, SV; Thomas, SM | 1 |
| Baumeister, P; Harréus, U; Heinrich, K; Märte, M; Reiter, M; Schwenk-Zieger, S | 1 |
| Fu, Z; Ge, H; Liu, H; Sun, Z | 1 |
| Amagaya, S; Chang, CM; Chang, PY; Chen, MY; Jao, HY; Kuo, SC; Lee, CY; Lu, CC; Tu, MG; Yang, JS | 1 |
| Chen, X; Duvvuri, U; Fung, C; Grandis, JR | 1 |
| Beckler, AD; Carlson, HT; Francom, CR; Jameson, MJ; Khalil, AA; Mendez, RE; Stuart, MM; Taniguchi, LE; Thomas, CY; VanKoevering, KK | 1 |
| Arteaga, CL; Barbieri, CE; Matheny, KE; Pietenpol, JA; Sniezek, JC | 1 |
| Hamakawa, H; Li, C; Mihara, M; Nakashiro, K; Shintani, S; Terakado, N; Yano, J | 2 |
| Purdom, M | 1 |
| Kataoka, K; Kurabayashi, T; Kuribayashi, A; Miura, M | 1 |
| Nelson, NJ | 1 |
| Couzin, J | 1 |
| Chandra, NR; Efferth, T; Gebhart, E; Konkimalla, VB; Suhas, VL | 1 |
| Iwase, M; Kondo, G; Nagumo, M; Ohashi, M; Shintani, S; Takaoka, S; Uchida, M; Watanabe, H; Yoshiba, S | 1 |
| Iwase, M; Kondo, G; Nagumo, M; Ohashi, M; Takaoka, S; Uchida, M; Watanabe, H; Yoshiba, S | 1 |
| Chen, X; Li, N; Newman, RA; Sood, S; Sun, Z; Yang, CS; Yang, P | 1 |
| Ge, HB; Li, P; Sun, Z | 1 |
| Fujita, S; Hiraishi, Y; Kiga, N; Matsumoto, T; Nakatani, K; Negoro, K; Tojyo, I; Wada, T | 1 |
| Huang, PC; Modest, EJ; Papathanasopoulos, N; Rosowsky, A | 1 |
| Modest, EJ; Rosowsky, A | 1 |
4 review(s) available for quinazolines and Cancer of Mouth
| Article | Year |
|---|---|
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Management of acneiform rashes related to gefitinib therapy.
Topics: Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dermatologic Agents; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mouth Neoplasms; Prognosis; Quinazolines; Skin Care | 2004 |
Diagnosis and therapy of oral squamous cell carcinoma.
Topics: Age Factors; Alcohol Drinking; Antineoplastic Agents; Aporphines; Azo Compounds; Berberine; Carcinoma, Squamous Cell; Chromosome Aberrations; Crystallography, X-Ray; Databases, Factual; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Mouth Neoplasms; Neoplasm Proteins; Nucleic Acid Hybridization; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Stilbenes; Structure-Activity Relationship | 2007 |
Synthesis and biological activity of tricyclic antifolate compounds with fixed geometry.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Chickens; Enterococcus faecalis; Folic Acid Antagonists; Humans; Leukemia L1210; Liver; Malaria; Mammary Neoplasms, Experimental; Mice; Mouth Neoplasms; Pyrimethamine; Quinazolines; Structure-Activity Relationship | 1971 |
33 other study(ies) available for quinazolines and Cancer of Mouth
| Article | Year |
|---|---|
The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Glycation End Products, Advanced; Humans; Mice; Mice, Nude; Mouth Neoplasms; Quinazolines; Receptor for Advanced Glycation End Products; Signal Transduction | 2021 |
Evaluation of anti-EGFR potential of quinazoline derivatives using molecular docking: An in silico approach.
Topics: Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Ligands; Molecular Docking Simulation; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2022 |
Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Hepatocyte Growth Factor; Humans; Indoles; Mouth Neoplasms; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pseudopodia; Quinazolines; Signal Transduction; Sulfonamides; Tyrphostins | 2017 |
The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mouth Neoplasms; Quinazolines | 2017 |
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred NOD; Mouth Neoplasms; Phenotype; Phosphoproteins; Precision Medicine; Quinazolines; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2017 |
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors.
Topics: Biomarkers, Pharmacological; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Mouth Neoplasms; Phosphorylation; Plakins; Polymorphism, Single Nucleotide; Quinazolines; Signal Transduction | 2019 |
Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Mouth Neoplasms; Phosphorylation; Quinazolines; Stem Cells; Tumor Microenvironment; Tyrphostins | 2014 |
Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Autophagy; Azepines; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Mice, SCID; Mouth Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
In Vitro Assessment of the Anticancer Potential of Evodiamine in Human Oral Cancer Cell Lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Mitochondria; Morpholines; Mouth Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Plant Extracts; Poly(ADP-ribose) Polymerases; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
Topics: Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Gene Expression Profiling; Humans; Hydroxybutyrates; Immunohistochemistry; Laryngeal Neoplasms; Mouth Neoplasms; Mutation; Purines; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Triazines | 2016 |
Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Mice, Nude; Mouth Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin D2; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Mouth Neoplasms; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2016 |
Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Autophagy; Carcinoma, Squamous Cell; Caspase 3; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Gefitinib; HL-60 Cells; Humans; Methotrexate; Mitoxantrone; Mouth; Mouth Neoplasms; Phytotherapy; Plant Extracts; Quinazolines; Sodium Fluoride; Tumor Cells, Cultured | 2009 |
Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Immunohistochemistry; Mice; Mice, Inbred CBA; Mouth Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor | 2010 |
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.
Topics: 4-Nitroquinoline-1-oxide; Animal Feed; Animals; Carcinogens; Carcinoma, Squamous Cell; Commiphora; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Immunoenzyme Techniques; Mice; Mice, Inbred CBA; Mouth Neoplasms; Plant Extracts; Plant Gums; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2011 |
The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Cetuximab; Cisplatin; DNA Damage; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha; Up-Regulation; Young Adult | 2011 |
Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cheek; Cricetinae; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mouth Neoplasms; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Wound Healing | 2012 |
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes | 2012 |
Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cyclin D; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor I; Mouth Neoplasms; Oncogene Protein v-akt; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; S Phase; Subcellular Fractions | 2013 |
Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mouth Neoplasms; Phosphoproteins; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Signal Transduction; Trans-Activators; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Flow Cytometry; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; S Phase; Tumor Suppressor Proteins; Up-Regulation | 2004 |
Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; GRB2 Adaptor Protein; Heparin-binding EGF-like Growth Factor; Humans; Insulin-Like Growth Factor I; Intercellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Mouth Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; Receptor Cross-Talk; Receptor, IGF Type 1; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tyrphostins | 2004 |
Years of research come to fruition with launch of oral cancer prevention trial.
Topics: Animals; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Proteins; Mouth Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor Cross-Talk; Signal Transduction; Sulfonamides | 2006 |
Cancer research. Fake data, but could the idea still be right?
Topics: Aneuploidy; Antineoplastic Agents; Controlled Clinical Trials as Topic; Erlotinib Hydrochloride; Genetic Markers; Humans; Loss of Heterozygosity; Mouth Diseases; Mouth Neoplasms; Quinazolines; Risk Factors; Scientific Misconduct | 2006 |
Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; Enzyme Inhibitors; ErbB Receptors; Humans; Inhibitor of Apoptosis Proteins; Mouth Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tyrphostins | 2007 |
Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cetuximab; Enzyme Inhibitors; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Humans; Mouth Neoplasms; Neoplasm Proteins; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; Tumor Cells, Cultured; Tyrphostins | 2008 |
Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Carcinogens; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cheek; Cricetinae; Dinoprostone; ErbB Receptors; Humans; Male; Mouth Mucosa; Mouth Neoplasms; Quinazolines; Receptor, ErbB-2 | 2008 |
[Inhibiting effects of GW2974 on DMBA-induced hamster buccal pouch carcinogenesis].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinoma, Squamous Cell; Cricetinae; Disease Models, Animal; Male; Mouth Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2007 |
EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Mouth Neoplasms; Quinazolines; Tyrphostins | 2008 |
Quinazolines. 12. 1,3-Diaminobenzo(f)quinazolines containing long-chain alkyl or chloro substituents on the central ring. Synthesis and biological evaluation as candidate antifolate and antimalarial agents.
Topics: Animals; Antimalarials; Carcinoma; Cell Line; Folic Acid Antagonists; Humans; Lactobacillus; Malaria; Mice; Mouth Neoplasms; Pediococcus; Plasmodium berghei; Quinazolines; Streptococcus; Structure-Activity Relationship | 1974 |